Operational Costs Compared: SG&A Analysis of Biogen Inc. and TG Therapeutics, Inc.

A Decade of SG&A: Biogen Inc. vs. TG Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Biogen Inc. and TG Therapeutics, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Biogen, a stalwart in the industry, consistently allocated substantial resources, peaking in 2021 with a 38% increase from 2014. In contrast, TG Therapeutics, a burgeoning player, demonstrated a more volatile pattern, with a staggering 522% rise in SG&A expenses from 2014 to 2023. This reflects their aggressive growth strategy and market expansion efforts. As Biogen focuses on maintaining its market dominance, TG Therapeutics is investing heavily in its future. This analysis underscores the diverse approaches companies take in navigating the competitive pharmaceutical sector, highlighting the balance between cost management and strategic investment.